Iopofosine i-131 is a small molecule commercialized by Cellectar Biosciences, with a leading Phase II program in Multiple Myeloma (Kahler Disease). According to Globaldata, it is involved in 10 clinical trials, of which 5 were completed, 4 are ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of Iopofosine i-131’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Iopofosine i-131 is expected to reach an annual total of $198 mn by 2034 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Iopofosine i-131 Overview
Iopofosine I-131 (CLR-131) is under development for the treatment of waldenstrom macroglobulinemia, refractory and relapsed multiple myeloma, chronic lymphocytic leukemia, Hodgkin lymphoma, small lymphocytic lymphoma, lymphoplasmacytic lymphoma (LPL), primary and secondary central nervous system lymphoma, marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), solid tumors, neuroblastoma, pediatric diffuse intrinsic pontine glioma, sarcomas including rhabdomyosarcoma, Ewing's sarcoma, osteosarcoma, lymphomas and malignant brain tumors, high-grade glioma, diffuse large B-cell lymphoma (DLBCL), mycosis fungoides, head and neck cancer squamous cell carcinoma. The drug candidate is radiolabeled compound administered through intravenous route in the form of solution. It comprises of PLE, 18-(p-[I-131] iodophenyl) octadecyl phosphocholine, covalently labelled with iodine-131. It is being developed based on Phospholipid Drug Conjugate (PDC) delivery platform.
The drug candidate was also under development for the treatment of non-small cell lung cancer, breast cancer, soft tissue sarcoma, colorectal cancer, gastric cancer, prostate cancer, ovarian cancer and esophageal cancer.
Cellectar Biosciences Overview
Cellectar Biosciences (Cellectar) is a biopharmaceutical company. It focuses on developing innovative cancer treatments using its proprietary phospholipid ether drug conjugate (PDC) delivery platform, which targets specific tumor cell changes for effective, selective therapy. The company’s lead product candidate, iopofosine I 131, delivers iodine-131 directly to cancer cells, minimizing healthy tissue exposure. Iopofosine is being evaluated for several indications, including lymphoplasmacytic lymphoma (LPL), Waldenstrom’s macroglobulinemia (WM), relapsed/refractory multiple myeloma (r/r MM), and relapsed/refractory diffuse large B-cell lymphoma (DLBCL). It is also being studied for neuroblastoma, soft tissue sarcomas, and other pediatric cancers. Cellectar is headquartered in Florham Park, New Jersey, the US.
The operating loss of the company was US$39 million in FY2023, compared to an operating loss of US$28.8 million in FY2022. The net loss of the company was US$38 million in FY2023, compared to a net loss of US$28.6 million in FY2022.
For a complete picture of Iopofosine i-131’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.